Total Payments
$105,152
2024 Payments
$18,430
Companies
81
Transactions
747
Medicare Patients
5,938
Medicare Billing
$1.8M
Payment Breakdown by Category
Other$53,434 (50.8%)
Consulting$28,407 (27.0%)
Food & Beverage$16,449 (15.6%)
Travel$6,064 (5.8%)
Education$797.64 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,289 | 13 | 46.9% |
| Consulting Fee | $28,407 | 12 | 27.0% |
| Food and Beverage | $16,449 | 677 | 15.6% |
| Travel and Lodging | $6,064 | 24 | 5.8% |
| Honoraria | $4,146 | 4 | 3.9% |
| Education | $797.64 | 17 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic USA, Inc. | $19,948 | 30 | $0 (2020) |
| Seagen Inc. | $15,486 | 37 | $0 (2023) |
| Astellas Pharma US Inc | $12,500 | 21 | $0 (2024) |
| Celgene Corporation | $10,413 | 51 | $0 (2024) |
| GENZYME CORPORATION | $9,206 | 19 | $0 (2024) |
| Coherus Biosciences Inc. | $7,060 | 13 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $5,588 | 42 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,393 | 33 | $0 (2024) |
| ABBVIE INC. | $2,488 | 8 | $0 (2024) |
| Genentech USA, Inc. | $2,077 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,430 | 167 | Astellas Pharma US Inc ($12,265) |
| 2023 | $30,882 | 234 | Seagen Inc. ($13,992) |
| 2022 | $5,429 | 74 | CTI BioPharma Corp. ($1,466) |
| 2021 | $6,718 | 27 | Coherus Biosciences Inc. ($5,833) |
| 2020 | $5,065 | 27 | Novartis Pharmaceuticals Corporation ($1,903) |
| 2019 | $33,307 | 90 | Medtronic USA, Inc. ($19,755) |
| 2018 | $1,596 | 74 | AstraZeneca Pharmaceuticals LP ($231.92) |
| 2017 | $3,726 | 54 | AstraZeneca Pharmaceuticals LP ($2,176) |
All Payment Transactions
747 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $26.33 | General |
| 12/17/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $23.76 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.19 | General |
| Category: Hematology | ||||||
| 11/22/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $30.89 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/19/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.35 | General |
| Category: Hematology/Oncology | ||||||
| 11/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Padcev (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,425.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $115.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.47 | General |
| Category: Hematology | ||||||
| 11/13/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $33.44 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $26.27 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo, Tecentriq | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: BioOncology | ||||||
| 11/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $34.20 | General |
| Category: Oncology | ||||||
| 11/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.75 | General |
| Category: Hematology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $28.18 | General |
| 10/25/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.22 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 2,381 | 81,821 | $6.0M | $1.4M |
| 2022 | 28 | 1,431 | 11,404 | $685,169 | $156,554 |
| 2021 | 10 | 899 | 1,531 | $427,173 | $102,206 |
| 2020 | 12 | 1,227 | 2,178 | $599,803 | $132,482 |
Total Patients
5,938
Total Services
96,934
Medicare Billing
$1.8M
Procedure Codes
102
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 20,400 | $3.2M | $884,841 | 27.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 29 | 6,180 | $395,520 | $115,092 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 339 | 1,199 | $467,610 | $114,916 | 24.6% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 13 | 678 | $443,412 | $59,302 | 13.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 91 | 463 | $194,923 | $45,066 | 23.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 19 | 2,100 | $155,400 | $34,981 | 22.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 173 | 173 | $88,057 | $21,112 | 24.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 188 | 290 | $80,330 | $18,330 | 22.8% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 55 | 244 | $51,240 | $18,120 | 35.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 64 | 554 | $57,062 | $12,364 | 21.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 439 | 1,512 | $43,848 | $11,477 | 26.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 38 | 161 | $33,005 | $7,948 | 24.1% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 17 | 420 | $50,400 | $7,632 | 15.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 138 | $28,704 | $6,660 | 23.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 13 | 3,640 | $21,840 | $5,024 | 23.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 23 | 96 | $16,992 | $4,028 | 23.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 31 | 165 | $27,060 | $3,621 | 13.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $13,460 | $3,224 | 23.9% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 14 | 996 | $13,944 | $3,150 | 22.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 267 | $17,889 | $2,910 | 16.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 29 | 179 | $11,635 | $2,853 | 24.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 185 | 260 | $2,340 | $2,167 | 92.6% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 20 | 15,900 | $63,600 | $1,939 | 3.0% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 15 | 900 | $6,300 | $1,697 | 26.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 13 | 13 | $7,059 | $1,695 | 24.0% |
About Dr. Sreekanth Reddy, MD
Dr. Sreekanth Reddy, MD is a Hematology & Oncology healthcare provider based in Vidalia, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437199965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sreekanth Reddy, MD has received a total of $105,152 in payments from pharmaceutical and medical device companies, with $18,430 received in 2024. These payments were reported across 747 transactions from 81 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($49,289).
As a Medicare-enrolled provider, Reddy has provided services to 5,938 Medicare beneficiaries, totaling 96,934 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Vidalia, GA
- Active Since 06/06/2006
- Last Updated 01/07/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437199965
Products in Payments
- OSTEOCOOL RF ABLATION (Device) $20,368
- TUKYSA (Drug) $14,886
- Padcev (Drug) $12,240
- Revlimid (Drug) $9,499
- ENJAYMO (Biological) $7,361
- MEKINIST (Drug) $3,060
- TAGRISSO (Drug) $2,323
- ADAKVEO (Biological) $1,903
- OPDIVO (Biological) $1,665
- ENHERTU (Biological) $1,627
- Vonjo (Drug) $1,466
- POLIVY (Biological) $1,260
- Tavalisse (Drug) $1,170
- KEYTRUDA (Biological) $1,161
- ELREXFIO (Drug) $1,132
- REBLOZYL (Biological) $657.91
- SIR-Spheres Microspheres (Device) $586.13
- ADCETRIS (Biological) $493.64
- CABOMETYX (Drug) $447.15
- Nubeqa (Drug) $370.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.